iBio Inc, a biotechnology company incorporated in Delaware, filed a Form 8-K report with the U.S. Securities and Exchange Commission (SEC) on January 8, 2024. The report announced the update of iBio's corporate presentation, which includes forward-looking statements under the safe harbor provisions. The updated presentation, furnished as Exhibit 99.1, is not considered filed for liability purposes and will not be incorporated into any SEC filings. The presentation outlines iBio's technology platform, which focuses on antibody therapeutics powered by machine learning, aiming to address complex targets and improve safety and developability. The company's pipeline includes preclinical programs targeting various diseases, with a focus on oncology, autoimmune, and vaccine applications. iBio's business model involves strategic partnerships, proprietary pipeline...Show More

iBio Inc, a biotechnology company incorporated in Delaware, filed a Form 8-K report with the U.S. Securities and Exchange Commission (SEC) on January 8, 2024. The report announced the update of iBio's corporate presentation, which includes forward-looking statements under the safe harbor provisions. The updated presentation, furnished as Exhibit 99.1, is not considered filed for liability purposes and will not be incorporated into any SEC filings. The presentation outlines iBio's technology platform, which focuses on antibody therapeutics powered by machine learning, aiming to address complex targets and improve safety and developability. The company's pipeline includes preclinical programs targeting various diseases, with a focus on oncology, autoimmune, and vaccine applications. iBio's business model involves strategic partnerships, proprietary pipeline development, and exclusive platform licensing. The company highlighted its AI-driven discovery tech stack, including patented epitope-engineering technology and antibody optimization technologies. iBio's financial highlights include a reduction in costs and a majority of debt secured by property for sale. The company's stock, with the trading symbol IBIO, is registered on the NYSE American exchange.